Figure 1.

Comparison of the prevalence of drugs used at baseline (left panel) and ever (right panel) among CVD +ve and CVD −ve patients.

bDMARDs +ve, patients who used biological disease-modifying anti-rheumatic drugs; bDMARDs -ve, patients who did not use biological disease-modifying anti-rheumatic drugs; CVD +ve, patients who developed cardiovascular events; CVD –ve, patients who did not develop cardiovascular events; MTX+ve, patients who used methotrexate; MTX-ve, patients who did not use methotrexate; NSAIDs+ve, patients who used non-steroidal anti-inflammatory drugs; NSAIDs-ve, patients who did not use non-steroidal anti-inflammatory drugs.